Key result
SYNTAX Score II outperforms the anatomical score in predicting 3-year major events after LM/3VD PCI.
Why the study?
The impact of the SYNTAX score and SYNTAX score II in patients undergoing PCI with second-generation everolimus-eluting stents had not been fully validated.
Does SYNTAX Score II improve prediction of clinical outcomes compared to the original SYNTAX Score in patients with left main and/or 3-vessel disease undergoing PCI with everolimus-eluting stents?
Cohort (n=1,248)
Yes
Does SYNTAX Score II improve prediction of clinical outcomes compared to the original SYNTAX Score in patients with left main and/or 3-vessel disease undergoing PCI with everolimus-eluting stents?
Answers are grounded in this paper and cite their sources.
SYNTAX Score II is superior to the original SYNTAX Score for predicting patient-oriented composite outcomes at 3 years in patients with complex coronary artery disease treated with contemporary everolimus-eluting stents.
BACKGROUND AND OBJECTIVES: The impact of SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery score (SS) and SS II in patients who receive percutaneous coronary intervention with second-generation everolimus-eluting stents (EES) has not been fully validated. METHODS: The SS, SS II were calculated in 1,248 patients with left main and/or 3-vessel disease treated with EES. Patient-oriented composite endpoint (POCE; all-cause death, any myocardial infarction (MI), any revascularization) and target lesion failure (TLF: cardiac death, target-vessel MI, target lesion revascularization) were analyzed. RESULTS: The mean SS was 21.1±9.6. Three-year POCE increased according to the SS group (15.2% vs. 19.9% vs. 27.4% for low (≤22), intermediate (≥23, ≤32), high (≥33) SS groups, p<0.001). By multivariate Cox proportional hazard analysis, SS group was an independent predictor of 3-year POCE (hazard ratio, 1.324; 95% confidence interval, 1.095-1.601; p=0.004). The receiver operating characteristic curves revealed that the SS II was superior to the SS for 3-year POCE prediction (area under the curve [AUC]: 0.611 vs. 0.669 for SS vs. SS II, p=0.019), but not for 3-year TLF (AUC: 0.631 vs. 0.660 for SS vs. SS II, p=0.996). In subgroup analysis, SS II was superior to SS in patients with cardiovascular clinical risk factors, and in those presenting as stable angina. CONCLUSIONS: The usefulness of SS and SS II was still valid in patients with left main and/or 3-vessel disease. SS II was superior to SS for the prediction of patient-oriented outcomes, but not for lesion-oriented outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00698607, ClinicalTrials.gov Identifier: NCT01605721.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2019) conducted a cohort in Left main and/or 3-vessel coronary artery disease (n=1,248). SYNTAX Score and SYNTAX Score II vs. Low SYNTAX Score was evaluated on 3-year patient-oriented composite endpoint (POCE; all-cause death, any myocardial infarction, any revascularization) (HR 1.324, 95% CI 1.095-1.601, p=0.004). The SYNTAX Score II was superior to the anatomical SYNTAX Score for predicting 3-year patient-oriented composite endpoints in patients with left main and/or 3-vessel disease undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: